Altimmune’s Experimental Drug Cuts Heavy Drinking Days in Key Phase 2 Trial
Altimmune’s experimental drug cut heavy drinking and helped weight loss in a mid-stage alcohol use disorder trial. Next: FDA meeting.
/ 7 items
#ALT↓
Leerink Initiates Outperform on Altimmune: Pemvidutide Poised for MASH Success with $10 Target
Pemvidutide demonstrates strong MASH resolution, weight loss, and cardiometabolic benefits, with significant analyst upside.
Altimmune Secures $75M in Direct Stock Offering to Advance Liver Disease Treatment
Altimmune raises $75 million through registered direct offering to fund Phase 3 trial of pemvidutide for MASH treatment and advance its liver disease therapy pipeline.
Altimmune Stock Surges on FDA Breakthrough Designation for Liver Disease Treatment
Altimmune shares jump 24% after FDA grants breakthrough therapy designation for pemvidutide, a promising treatment for MASH liver disease showing significant trial results.
Altimmune's MASH Drug Shows Promise in Extended Trial Despite Mixed Signals
Altimmune (ALT) reports 48-week results for pemvidutide in MASH trial, showing continued weight loss and liver fibrosis improvements, though some measures weakened from earlier data.
Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.